Table 1.

Characteristics of patients in included trials

Source	No. of patients		Median age	Male	Performance status		Therapeutic regimen	HR for DFS
	Experiment	Control	(Years)	(%)	ECOG0 (%)	ECOG1 (%)
EVIDENCE	151	132	60 vs 58	51 vs 42	31 vs 29	68 vs 70	Icotinib vs Chemo	0.37 (0.24 to 0.55)
ADAURA	339	343	64 vs 62	32 vs 28	64 vs 64	36 vs 36	Osimertinib vs Chemo	0.20 (0.14 to 0.30)
EVAN	51	51	59 vs 57	33 vs 39	41 vs 43	57 vs 55	Erlotinib vs Chemo	0.27 (0.14 to 0.51)
ADJUVANT	111	111	58 vs 60	40 vs 41	32 vs 20	65 vs 77	Gefitinib vs Chemo	0.60 (0.42 to 0.87)
IMpower010*	49	60	62 vs 62	66 vs 67	54 vs 57	46 vs 43	C+Atezo vs Chemo	0.99 (0.60 to 1.62)
IMPACT	NR	NR	NR	NR	NR	NR	Gefitinib vs Chemo	0.92 (0.67 to 1.28)
KEYNOTE-091*	39	34	65 vs 65	68 vs 69	NR	36 vs 42	C+Pembro vs Chemo	0.44 (0.23 to 0.84)

*Only included the population with EGFR mutations.

C+Atezo, chemotherapy+atezolizumab; Chemo, chemotherapy; C+Pembro, chemotherapy+pembrolizumab; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, Hazard ratio; No. of patients, Number of patients; NR, not reported; vs, versus.